All articles tagged with #vk2735
Viking Therapeutics' oral weight loss drug VK2735 showed promising weight reduction in a Phase 2 trial, but high rates of gastrointestinal side effects and discontinuation have disappointed investors.
Viking Therapeutics' stock dropped 37% after revealing that its obesity drug VK2735 had a high dropout rate in a Phase 2 trial, despite showing some efficacy in weight loss. The high discontinuation rate raised concerns about the drug's tolerability and competitive position compared to Eli Lilly's offerings, leading to investor skepticism about Viking's prospects in the oral obesity market.
Viking Therapeutics announced positive top-line results from a Phase 2 trial of VK2735, an oral tablet for obesity, showing significant weight loss up to 12.2% over 13 weeks, with good safety and tolerability, supporting further development for metabolic disorders.
Viking Therapeutics' experimental weight-loss tablet, VK2735, showed promising results in a small early-stage trial, with the highest 40-milligram dose leading to a 3.3% weight loss in participants. The company's shares rose 15% following the news. Viking plans to continue testing higher doses and expects to initiate a mid-stage study in obese patients later this year. The drug's oral version could offer a more convenient option for patients, especially those who have achieved significant weight loss with the injectable version.
Viking Therapeutics announces positive results from a Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, showing up to 3.3% placebo-adjusted mean weight loss and low rates of gastrointestinal adverse events after 28 days of oral tablet formulation. The company plans to initiate a Phase 2 trial in obesity later this year and will host a conference call to discuss the results. VK2735 demonstrated promising early weight loss and tolerability, with potential for additional weight loss with longer treatment duration and higher doses.
Viking Therapeutics' stock doubled after reporting positive results from a Phase 2 trial of its weight-loss drug VK2735, showing statistically significant reductions in body weight at all doses compared to placebo, with patients losing up to 14.7% of their body weight after 13 weeks. The treatment was well-tolerated, and the company plans to discuss next steps with the FDA. The news positions Viking as a potential competitor in the weight-loss drug market, and the company is also developing a treatment for NASH.
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate an oral formulation of its dual GLP-1/GIP receptor agonist VK2735. The study will evaluate daily oral doses for 28 days and the results are expected to be available in the second half of 2023. The primary objective of the study is to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. The secondary objective is to evaluate the pharmacokinetics of orally administered VK2735 in healthy subjects.